Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MT1980 · 1 trial · 1 indication
Descriptive statistics comparing MT1980 \& placebo following a single dose of study drug. Number of subjects, number of events and severity of events to be reported
| Arm | Type | Description |
|---|---|---|
| Part 1 MT1980 | EXPERIMENTAL | - |
| Part 1 Placebo | PLACEBO_COMPARATOR | - |
| Part 2 MT1980 Dose Level 1 | EXPERIMENTAL | - |
| Part 2 MT1980 Dose Level 2 | EXPERIMENTAL | - |
| Part 2 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MT1980 | DRUG | single dose |
| Placebo | DRUG | single dose |
Inclusion Criteria: * Healthy volunteers with good physical and mental health * Body Mass Index 18 to 30 kg/m2 * Men \& women of child-bearing potential must agree to use adequate contraception * Willing \& able to provide written informed consent and to communicate and participate in the study Ex...
MT1980 is an investigational small molecule being developed for the treatment of neuroinflammatory response. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and its safety and efficacy are still being evaluated in human trials.
MT1980 is being developed by Icon Plc, a biopharmaceutical company listed on the NASDAQ under the ticker symbol ICLR. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of this investigational drug.
MT1980 is in Phase 1 clinical development. A Phase 1 trial has been completed, which involved 24 participants and was designed to assess the safety and pharmacokinetics of single doses of the drug. The drug remains investigational and is not yet approved for any use.
MT1980 has one completed clinical trial registered under NCT05429840, titled 'Safety & PK of Single Doses of MT1980'. This Phase 1 study enrolled 24 participants in the Netherlands, including healthy volunteers, and was a randomized, double-blind, placebo-controlled trial.
No alternative names for MT1980 have been reported. The drug is known solely by its developmental code name MT1980 and is not identified as being the same as any other marketed or investigational product.